Evangelista Laura, Basso Umberto, Maruzzo Marco, Novara Giacomo
Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Oncology 1 Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Eur Urol Focus. 2020 Jan 15;6(1):146-150. doi: 10.1016/j.euf.2018.08.004. Epub 2018 Aug 16.
Preliminary results have demonstrated that prostate-specific membrane antigen (PSMA) is highly expressed on the cell surface of the microvasculature of several solid tumors, including renal cell carcinoma (RCC).
To assess the role of PSMA positron emission tomography (PET)/computed tomography (CT) in RCC patients and to discuss its possible inclusion in the clinical management of these patients.
A systematic literature search was performed for studies on PET/CT in patients with RCC up to April 2018. MEDLINE databases, such as Pubmed, Web of Science, and Scopus were consulted using the following keywords: "Renal Cell Carcinoma" AND "PET/CT", "Renal Cancer" AND "PET/CT", "renal cancer" AND "PSMA PET/CT", and "renal cell carcinoma" AND "PSMA PET/CT".
Thirteen articles were retrieved from the available literature; the majority of them were relative to metastatic RCC (n=11/13, 85%) and eight of them were clinical cases, thus providing low-quality data. No diagnostic benefit of PSMA PET/CT was found in the evaluation of primary tumors. PSMA PET/CT may be a useful imaging modality in whole-body staging and restaging of patients with RCC and in the assessment of lesions that remained unclear on conventional imaging. Furthermore, PSMA PET/CT may predict the response to anti-angiogenic-targeted therapies.
The utility of PSMA-based PET imaging in the assessment of patients with RCC is encouraging. However, the available preliminary results will need to be addressed with larger prospective trials.
In this mini-review, we evaluated the usefulness of an alternative imaging technique for patients with renal cell cancer. We found that this new imaging modality may indeed be useful. We conclude that the preliminary data should be assessed by larger studies.
初步结果表明，前列腺特异性膜抗原（PSMA）在包括肾细胞癌（RCC）在内的几种实体瘤的微血管细胞表面高度表达。
评估PSMA正电子发射断层扫描（PET）/计算机断层扫描（CT）在RCC患者中的作用，并讨论其纳入这些患者临床管理的可能性。
对截至2018年4月的RCC患者PET/CT研究进行了系统的文献检索。使用以下关键词查询了MEDLINE数据库，如Pubmed、科学网和Scopus：“肾细胞癌”与“PET/CT”、“肾癌”与“PET/CT”、“肾癌”与“PSMA PET/CT”以及“肾细胞癌”与“PSMA PET/CT”。
从现有文献中检索到13篇文章；其中大多数与转移性RCC相关（n = 11/13，85%），其中8篇为临床病例，因此提供的是低质量数据。在原发性肿瘤评估中未发现PSMA PET/CT的诊断益处。PSMA PET/CT可能是RCC患者全身分期和再分期以及评估传统成像中仍不清楚的病变的有用成像方式。此外，PSMA PET/CT可能预测对抗血管生成靶向治疗的反应。
基于PSMA的PET成像在RCC患者评估中的实用性令人鼓舞。然而，现有的初步结果需要通过更大规模的前瞻性试验来解决。
在本综述中，我们评估了一种替代成像技术对肾细胞癌患者的有用性。我们发现这种新的成像方式可能确实有用。我们得出结论，初步数据应由更大规模的研究进行评估。
